GenSight Biologics Announces the Closing of its €1.0 Million Fundraising Supported by Existing Shareholders
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
PARIS, October 16, 2026--Regulatory News:
GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the closing of its EUR 1,000,000.208 fundraising (the "Fundraising"), announced on October 8, 2026.
The Fundraising resulted in the issuance of:
2,597,404 ordinary shares (actions ordinaires) of the Company (the "Offered Shares"), which were admitted to trading on Euronext Paris on October 12, 2026 (ISIN FR0013183985/SIGHT);
11,940,300 pre-funded warrants (the "Offered Pre-Funded Warrants") giving the right to subscribe to 11,940,300 additional ordinary shares; and
14,537,704 warrants (the "Offered Investor Warrants") giving the right to subscribe to 7,268,852 additional ordinary shares.
The Offered Investor Warrants and the Offered Pre-Funded Warrants will not be admitted to trading on any venue.
Risk factors
The Company draws the attention of the public to the risk factors relating to the Company and its business described in its 2025 Universal Registration Document, which is available free of charge on the Company's website (https://www.gensight-biologics.com/) .
About GenSight Biologics S.A.
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. GS010 is currently in clinical development, has not to date been granted marketing authorization in France or any other jurisdiction, and is therefore not available commercially. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.